Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells

Anti-Cancer Drugs

Volumn 18, Issue 8, 2007, Pages 883-888

  Puglisi, Fabio ^a   Andreetta, Claudia ^a   Valent, Francesca ^a   Minisini, Alessandro Marco ^a   Rijavec, Erika ^a   Russo, Stefania ^a   Mansutti, Mauro ^a   Cardellino, Giovanni ^a   Pizzolitto, Stefano ^a   Di Loreto, Carla ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Anthracyclines; Breast cancer; Capecitabine; Docetaxel; Immunohistochemistry; Thymidine phosphorylase

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STROMA CELL; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; STROMAL CELLS; TAXOIDS; THYMIDINE PHOSPHORYLASE; UP-REGULATION;

EID: 34547690831     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32816ebede     Document Type: Article

References (28)

1. Toi M, Rahman MA, Bando H, Chow L. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6:158-166.
2. Van Cutsem E, Cunningham D, Hoff PM, Maroun J. Thymidine phosphorylase (TP) activation: convenience through innovation. Oncologist 2001; 6 (Suppl 4):1-2.
3. Sledge GW. What is targeted therapy? J Clin Oncol 2005; 23:1614-1615.
4. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H. Preparation of anti-tumor thymidine phosphorylase monoclonal antibody useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996; 19:1407-1411.
5. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
6. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
7. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
8. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, et al. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 2005; 14:1223-1230.
9. Tominaga T, Toi M, Ohashi Y, Abe O, on behalf of the 5′-BC study group. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 2002; 3:55-64.
10. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:4069-4078.
11. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonists chemotherapy. Pharmacogen J 2005; 5:226-243.
12. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
13. Toi M, Bando H, Horiguchi S, Takada M, Kataoka M, Ueno T, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004; 90:2338-2343.
14. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002; 20:2616-2623.
15. Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, et al. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2005; 11:1870-1876.
16. Han JY, Hong EK, Lee SY, Yoon SM, Lee DH, Lee JS. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 2005; 58:650-654.
17. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999; 83:127-134.
18. O'Shaughnessy BJ, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
19. Minisini AM, Di Loreto C, Mansutti M, Artico D, Pizzolitto S, Piga A, et al. Topoisomerase IIα and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett 2005; 224:133-139.
20. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G. Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue. Breast Cancer Res Treat 2004; 86:215-223.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
22. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
23. O'Neil BH, McLeod HL. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection? J Clin Oncol 2006; 24: 4051-4053.
24. Kurosumi M, Tabei T, Suemasu K, Inoue K, Kusawake T, Sugamata N, et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000; 7:945-948.
25. Nagaoka H, Iino Y, Takei H, Morishita Y. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 1998; 13:449-454.
26. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32:333-338.
27. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997; 57:570-572.
28. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000; 190:430-436.